Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Mouse NKG2D Antibody (CX5), FITC

Catalog #:   FMD72121 Specific References (50) DATASHEET
Host species: Rat
Isotype: IgG1, kappa
Applications: ELISA, FCM
Accession: O54709
Overview

Catalog No.

FMD72121

Species reactivity

Mouse

Host species

Rat

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

FITC

Target

NKG2-D type II integral membrane protein, Killer cell lectin-like receptor subfamily K member 1, NK cell receptor D, NKG2-D-activating NK receptor, CD314, Klrk1, Nkg2d

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

O54709

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

CX5

Data Image
References

Two major human phenotypes of MICA molecules and their differential activation to NK cells via NKG2D receptor., PMID:40458406

Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia., PMID:40430040

NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025

Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374

Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474

CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283

From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis., PMID:40236704

23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation., PMID:40116579

Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway., PMID:40049088

BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis., PMID:40021214

Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034

Natural killer cell engagers for cancer immunotherapy., PMID:39911822

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma., PMID:39904787

A New Antibody-Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia., PMID:39858511

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model., PMID:39763968

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495

Exosomal miR-552-5p Regulates the Role of NK Cells in EMT of Gastric Cancer via the PD-1/PD-L1 Axis., PMID:39744482

Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study., PMID:39724280

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab., PMID:39699928

Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862

γδ T cells in hematological malignancies: mechanisms and therapeutic strategies., PMID:39676818

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager., PMID:39628574

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757

Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands., PMID:39582357

MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation., PMID:39575256

Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029

Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects., PMID:39534532

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576

IL-15-induced CD38+HLA-DR+CD8+ T cells correlate with liver injury via NKG2D in chronic hepatitis B cirrhosis., PMID:39416768

CD56-targeted in vivo genetic engineering of natural killer cells mediates immunotherapy for acute myeloid leukemia., PMID:39363829

Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527

Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic., PMID:39291926

Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study., PMID:39279428

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies., PMID:39267747

A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39211152

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534

Isolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy., PMID:39170144

Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity., PMID:39116667

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity., PMID:39112670

Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer., PMID:39020183

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592

Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234

Memory-like differentiation enhances NK cell responses against colorectal cancer., PMID:38737793

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands., PMID:38731936

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells., PMID:38724464

Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611

Datasheet
$ 225
Product specifications
50 T 225 100 T 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Mouse NKG2D Antibody (CX5), FITC [FMD72121]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only